P001 - Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study
| Autor: | Lüftner, D., Tesch, H., Schmidt, M., Hartkopf, A., Streicher, S., Resch, A., Genovese, L., Rosé, C., Valenti, R., Harbeck, N. |
|---|---|
| Zdroj: | In The Breast April 2021 56 Supplement 1:S17-S17 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect